TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06249451

Intervention type: OTHER
Group type: OTHER
Intervention: Checklist-based phone calls
Description: The treating doctor will be called on day 1 and 12 after SAB diagnosis to point out the standard of care (as per our evidence-based in-hospital standard operating procedure (SOP)) for SAB.~On day 2 and 6 after SAB diagnosis, there will be additional phone calls if clinical management does not follow hospital guidelines.~The study team will also leave comments in the medical charts of the respective patients if the management does not follow hospital guidelines.
Study: NCT04170335

Intervention type: PROCEDURE
Intervention: Bariatric surgery
Description: Patients selected and consented for elective bariatric surgery will undergo standard of care preoperative mammogram, as well as inflammatory markers measurements and breast cancer risk score calculation. Post bariatric surgery the patients will have follow up mammogram, inflammatory markers, and breast cancer risk score calculation
Study: NCT05628961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOPO 14-1
Description: HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOPO 14-1
Description: HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HOPO 14-1
Description: HOPO 14-1 contains the active pharmaceutical ingredient (API) 3, 4, 3-LI(1, 2-HOPO) formulated with a permeability enhancer, sodium oleate, in capsule form.
Study: NCT05515458

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Oral single dose 48 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chiglitazar
Description: Oral single dose 48 mg
Study: NCT06167382

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnare
Description: Demographic Survey Form,the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+),Goniometric Measurements, Digital Dynamometer Measurements, Hand Grip Measurements, Hand Reaction Measurements, Dexterity and Function Measurements, Jamar Handheld Dynomometer Measurement, Pinchmeter Measurement, Purdue Pegbord Test, Minnesota Manuel Skill Test, Nelson Hand Reaction Test, Modified Borg Scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Device: Arm Ergometer
Description: Participants will sign a consent form approved by the ethics comittee. Before data collection height, weight, daily computer usage time, dominant hand, body mass index, heart rate, blood pressure and saturation values be recored. Before arm ergometer exercise, the muscle strength, hand grip strength, joint range of motion, dexterity and reaction speed will be evaluated. The dexterity and reaction speed will be done with Minnesota Manuel Skill Test, Purdue Pegbord Test and Nelson Hand Reaction Test.Participants will be training at least 24 hours apart at 60%, 70%, and 80% of exercise intensity maximum heart rate on arm ergometer. The tests will repeat at the same time with a maximum deviation of 1 hour on 3 different days. At the end of arm ergometer exercise, the necessary evaluations will be made again and the participants will be rest for 15 minutes. 15 minutes after the participants rested, the necessary evaluations will be made again.
Study: NCT06238999

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Restoration of non-carious cervical lesions
Description: Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Restoration of non-carious cervical lesions
Description: Non-carious cervical lesions will be treated with the experimental TM Flow or the well-established Tetric EvoFlow. The treatment workflow is very similar to other flowable composites.
Study: NCT05823883

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6014
Description: Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DW6014
Description: Drug: DW6014 Single oral administration of DW6014 in fed condition~Drug: Empagliflozin and Metformin Combination oral administration of Empagliflozin and Metformin in fed condition
Study: NCT06475222

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study 1: Facial serum with alpha albutin
Description: Applying with facial serum with 2% alpha albutin as active comparator daily for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 1: Facial serum with Tubtim Chumpae rice extract
Description: Applying with facial serum with Tubtim Chumpae rice extract as experimental intervention daily for 12 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 2: Facial mask with Hom Pathum rice extract
Description: Applying with facial mask with Hom Pathum rice extract as experimental intervention for 30 min/day, 2 days/week for 12 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Study 3: Control jelly
Description: Consumption with control jelly as active comparator at 3.5 g/kg body weight.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 3: Jelly with Tubtim Chumpae rice
Description: Consumption with jelly with Tubtim Chumpae rice as experimental intervention at 3.5 g/kg body weight.
Study: NCT05264896

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU, Leucovorin, Oxaliplatin, Docetaxel
Description: FLOT 4 cycles pre and post radical gastrectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XELOX
Description: XELOX 8 cycles post radical gastrectomy
Study: NCT04926727

Intervention type: OTHER
Intervention: Survey
Description: Observational study
Study: NCT04884932

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 30 kHz stimulation (Myomed 932, Enraf-Nonius)
Description: A charge-balanced, symmetric, biphasic sinusoidal current without modulation will be delivered at a frequency of 30 kHz. The stimulation intensity will be defined as that sufficient to produce a strong but comfortable sensation, just below motor threshold, over the median nerve through the electrotherapy device Myomed 932. (Enraf-Nonius, Delft,Netherlands)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham stimulation (Myomed 932, Enraf-Nonius)
Description: Sham stimulation will be delivered at a frequency of 30 kHz only during the first 30 seconds.
Study: NCT05731531

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROGASTROGRAPHY
Description: Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROGASTROGRAPHY
Description: Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROGASTROGRAPHY
Description: Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROGASTROGRAPHY
Description: Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.

Intervention type: DEVICE
Group type: OTHER
Intervention: ELECTROGASTROGRAPHY
Description: Electrogastrography as a new tool to customize choice of Bariatric therapies by determining success or failure based on GMA and WLST results has not been studied. GMA measures the normal or depleted gastric ICCs and the WLST measures gastric capacity, objective measures that may be important to predict success of Bariatric procedures and thus to help with patient selection to maximize efficacy and minimize side effects.
Study: NCT05856461

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
Study: NCT06243627

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen C Color 2.0 SPF 70
Description: Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen C Color 2.0 SPF 70
Description: Sunscreen C color 2.0 SPF 70 will be applied topically on half of the face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen C Color 3.0 SPF 70
Description: Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen C Color 3.0 SPF 70
Description: Sunscreen C color 3.0 SPF 70 will be applied topically on half of the face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen M Very Light SPF 50
Description: Sunscreen M very light SPF 50 will be applied topically on half of the face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen M Very Light SPF 50
Description: Sunscreen M very light SPF 50 will be applied topically on half of the face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen M Golden Color SPF 50
Description: Sunscreen M golden color SPF 50 will be applied topically on half of the face.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sunscreen M Golden Color SPF 50
Description: Sunscreen M golden color SPF 50 will be applied topically on half of the face.
Study: NCT05856461

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Pulmonary vein isolation
Description: Circumferential pulmonary vein isolation procedure using 3D navigation systems with entrance and exit block verification
Study: NCT05803980

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbiota transplantation (FMT)
Description: Single FMT infusion via colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fecal microbiota transplantation (FMT)
Description: Single FMT infusion via colonoscopy
Study: NCT04969367

Intervention type: OTHER
Intervention: Medical Device Usage and Evaluation
Description: Wear activity monitor (Fitbit)

Intervention type: PROCEDURE
Intervention: Biospecimen Collection
Description: Undergo collection of blood samples

Intervention type: OTHER
Intervention: Questionnaire Administration
Description: Complete questionnaires

Intervention type: OTHER
Intervention: Quality-of-Life Assessment
Description: Complete questionnaires
Study: NCT05201235

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MAEVAD
Description: MAEVAD is a training device which aims to improve VA span as a prerequisite for learning to read. By increasing the number of distinct visual elements that can be processed simultaneously during fixation, MAEVAD is intended to improve the reading (accuracy and fluency) and spelling (lexical) performance of dyslexics who have a VA span deficit. MAEVAD is designed to be used in total autonomy by dyslexic children with a VA span disorder. The therapy takes place over 6 weeks with 5 sessions of 15 minutes per week. In order to improve compliance, the therapy has been integrated into le Royaume d'Adelia, a serious game where the child will be able to collect materials at the end of each session that will allow him to create objects to customise a character.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: DeCaLigne
Description: DéCaLigne is an intervention programme for the discovery of calculation with the number line. The objectives are to improve numerical representations in the form of a number line and to improve addition and subtraction skills. The overall principle is to move numbers or calculation results on a number line. This training does not stimulate VA span or the phonological dimensions involved in reading. This therapy is being adapted to be used in total autonomy at home and to correspond to the MAEVAD therapy in duration (5 sessions of 15 minutes per week for 6 weeks). It has also been integrated into the royaume d'Adelia in order to control the motivational effect of the serious game.
Study: NCT04970836

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant hepatitis B vaccine
Description: Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant hepatitis B vaccine
Description: Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: recombinant hepatitis B vaccine
Description: Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
Study: NCT05856461

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Sham pulmonary artery denervation
Description: Sham pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries with creation of the false ablation points. No true ablation lesions will be performed in the pulmonary artery

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pulmonary artery denervation
Description: Pulmonary artery denervation procedure includes 3D reconstruction of the right ventricular outflow tract, main, left and right pulmonary arteries and 3 circles of ablation lesions (bifurcation of the main pulmonary artery, left and right pulmonary arteries)
Study: NCT04970836

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: recombinant hepatitis B vaccine
Description: Hepatitis B vaccine (Engerix-B) will be administered to the eligible participants by 4 groups. Each case will be tracked for 12 months, at 0, 7-10 days, 28 days, 24-28 weeks, 48-52 weeks anti-HBs titer concentration and 4 follow-up questionnaires.
Study: NCT05092360

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemvaleukin and Pembrolizumab Combination
Description: Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes and Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab: 200 mg; Day 1 of 21-day cycles; IV infusion over 30 minutes

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Nemvaleukin
Description: Nemvaleukin: 6 µg/kg/day; Days 1 through 5 of 21-day cycles; IV infusion over 30 minutes

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pegylated Liposomal Doxorubicin (PLD)
Description: 40 mg/m2; Day 1 of 28-day cycles; IV infusion; 1 mg/min (Cycle 1); 60 min infusion (Cycles 2+)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: 80 mg/m2; Days 1, 8, 15, and 22 of 28-day cycles; IV infusion over 60 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topotecan
Description: 4 mg/m2; Days 1, 8, and 15 of 28-day cycles; or 1.25 mg/m2, Days 1 through 5 of 21-day cycles; IV infusion over 30 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: 1,000 mg/m2; Days 1 and 8 of 21-day cycles; IV infusion over 30 min
Study: NCT05256940

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing to Address Suicidal Ideation- Revised (MI-SI-R)
Description: Motivational Interviewing to Address Suicidal Ideation (MI-SI-R) was developed to help Veterans resolve ambivalence about living by increasing the motivation to live, that is delivered in three sessions in person, virtually, or by telephone.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced usual care (EUC)
Description: Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enhanced usual care (EUC)
Description: Enhanced usual care (EUC) includes safety plans administered or reviewed by research therapists, care coordination, and access to a 24-hour crisis hotline.
Study: NCT04931173

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVA+OA versus IVA+MBP+OA
Description: Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: IVA+OA versus IVA+MBP+OA
Description: Non-inferiority RCT comparing IVA+OA+MBP vs IVA+OA to reduce surgical site infection following colon surgery
Study: NCT06543368

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Intra articular PRP Injection
Description: A total of 20 joints (estimated 10-15 patients) will receive injections, performed at day 0 and 3 weeks, for a total of two injections - two injections have demonstrated superior outcomes to one, and will increase our number of injections to improve the proof of feasibility. All subjects will receive ultrasound-guided intra-articular joint injections by an experienced sports medicine provider after local anesthesia with 1% lidocaine to the extra-articular structures, namely the skin and joint capsule, to increase comfort.
Study: NCT06535828

Intervention type: DEVICE
Intervention: AI and mechanic modeling
Description: The data collected from research tests on your blood and tumor samples will be used to develop an AI model for treatment selection.
Study: NCT06138561

Intervention type: BEHAVIORAL
Intervention: Geriatric-8 Survey
Description: A screening tool to evaluate frailty and at-risk participants by covering multiple domains that contribute to frailty, including mobility, functional status, pharmacologic burden, and underlying psychologic burden. A total score ranges from 0 to 17 with participants scoring \> 14 points are more likely to be fit, or having a better health status, while those scoring 0 - 14 would benefit from further comprehensive geriatric assessment.
Study: NCT05279027

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zirconium Zr 89 Crefmirlimab Berdoxa
Description: Zirconium Zr 89 Crefmirlimab Berdoxa PET/CT scans pre and post therapy initiation
Study: NCT04628416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PICO dressing
Description: Use of a portative miniature negative pressure dressing system named PICO® on the split-thickness skin graft of fibula free flap donor sites

Intervention type: DEVICE
Group type: OTHER
Intervention: Conventional dressing
Description: use of a conventional dressing (parrafin gauze) on the split-thickness skin graft of fibula free flap donor sites
Study: NCT06148714

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Provitalize Natural Menopause Probiotic
Description: Supplement containing a Probiotic blend of Bifidobacterium breve, Lactobacillus Gasseri, and Bifidobacterium animalis subsp. Lactis.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator containing Pure hydroxypropyl methylcellulose (HPmC) with food dye.
Study: NCT06138561

Intervention type: BEHAVIORAL
Intervention: National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)
Description: Patient reported, sixteen question survey focused on evaluation of quality of life in patients with bladder cancer.
Study: NCT06475222

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Study 3: Jelly with Hom Pathum rice
Description: Consumption with jelly with Hom Pathum rice as experimental intervention at 3.5 g/kg body weight.
Study: NCT06138561

Intervention type: BEHAVIORAL
Intervention: Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Description: Patient-reported questionnaire that evaluates cancer-specific toxicity, developed based upon Common Terminology Criteria for Adverse Events.
Study: NCT06561893

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Broccoli sprouts extract supplementation
Description: Intake of broccoli sprouts extract supplement (Brand: Source Naturals, Scotts Valley, CA 95066 - USA) in an acute dose (84 umol of glucoraphanin) before and after 2 weeks of probiotic or placebo supplementation, to assess sulforaphane bioavailability measured in urine metabolites

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Broccoli sprouts extract supplementation
Description: Intake of broccoli sprouts extract supplement (Brand: Source Naturals, Scotts Valley, CA 95066 - USA) in an acute dose (84 umol of glucoraphanin) before and after 2 weeks of probiotic or placebo supplementation, to assess sulforaphane bioavailability measured in urine metabolites
Study: NCT06091657

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: intravenous injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine Hydrochloride
Description: intravenous injection
Study: NCT05023317

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strengths-based linkage to alcohol care
Description: SLAC is a behavioral intervention designed to link persons with substance use/misuse to care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual care
Description: Usual care consists of brief screening and intervention and/or standard referral to alcohol care